Modality
Multispecific
MOA
KRASG12Ci
Target
IL-13
Pathway
Lipid Met
PAHPompe
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Jul 2030
Phase 1Current
NCT03273035
2,535 pts·Pompe
2017-08→2027-10·Recruiting
NCT03585733
2,477 pts·Pompe
2024-12→2030-07·Not yet recruiting
5,012 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-271.6y awayPh2 Data· Pompe
2030-07-204.3y awayPh2 Data· Pompe
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Recruit…
P1/2
Not yet…
Catalysts
Ph2 Data
2027-10-27 · 1.6y away
Pompe
Ph2 Data
2030-07-20 · 4.3y away
Pompe
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03273035 | Phase 1/2 | Pompe | Recruiting | 2535 | SRI-4 |
| NCT03585733 | Phase 1/2 | Pompe | Not yet recr... | 2477 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |